Soleno Therapeutics, Inc. (SLNO) स्टॉक विश्लेषण

कंपनी का अवलोकन

Soleno Therapeutics, Inc. operates as a biopharmaceutical entity dedicated to the research, development, and commercialization of innovative therapeutic agents specifically designed for the management of rare diseases. This enterprise functions within the broader Healthcare sector, focusing on the specialized niche of the Biotechnology industry, which implies a high degree of scientific complexity and regulatory scrutiny. The company's current market capitalization stands at $2.72B, while its trailing twelve-month revenue generated was $190.40M, supported by a workforce of 182 employees. These valuation and revenue figures suggest that the market assigns a significant premium to the company's pipeline assets, particularly its lead product candidate VYKAT XR for Prader-Willi Syndrome, reflecting strong investor confidence in its potential to disrupt the rare disease treatment landscape despite the inherent risks associated with biotechnology ventures.

वित्तीय स्वास्थ्य

Soleno Therapeutics reported a net income of $20.48M against a revenue base of $190.40M, yielding an EBITDA of $16.97M, which reveals a cost structure where operating expenses are substantial relative to gross receipts yet managed to preserve profitability. The company generated positive free cash flow of $48.27M, indicating a strong capacity to fund operations and potentially finance future clinical trials or strategic acquisitions without relying heavily on external capital markets. Profitability analysis shows a gross margin of 98.6%, reflecting the low cost of goods sold typical in biotechnology, an operating margin of 44.1% demonstrating efficient management of overhead costs, and a profit margin of 11.0% that highlights the final bottom-line efficiency after all expenses. The balance sheet displays a robust liquidity position with $305.47M in cash against $52.55M in debt, resulting in a debt-to-equity ratio of 11.68 which suggests a leveraged capital structure common in capital-intensive life sciences. A current ratio of 5.80 further underscores exceptional short-term liquidity, ensuring the company can comfortably meet its immediate financial obligations well beyond standard industry benchmarks. Finally, the Return on Equity stands at 6.0% while the Return on Assets is 2.1%, metrics that indicate management's effectiveness in generating returns from shareholder capital and utilizing the company's asset base respectively.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is 134.87, whereas the forward P/E is listed as -23.17, a divergence that implies analysts project significant future earnings adjustments or losses that will materially alter the company's valuation multiple in upcoming periods. The price-to-book ratio of 6.11 indicates that the market values the company at a significant premium over its tangible book value, a common occurrence for biotechnology firms with valuable intellectual property portfolios. Alternative valuation metrics such as the price-to-sales ratio of 14.29 and the EV/EBITDA of 145.14 suggest that investors are pricing Soleno based on its revenue generation potential and enterprise value rather than current earnings power, typical for companies in early growth phases. The stock has traded within a range defined by a 52-week high of $90.32 and a 52-week low of $29.43, providing context for the stock's recent price volatility and market sentiment over the past year. The beta value of -2.81 is a critical metric indicating that the stock's price moves with extreme volatility and an inverse relationship to the broader market, meaning it tends to rise when markets fall and fall when markets rise, presenting unique risk characteristics for portfolio construction.

Growth & Income

The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, meaning specific historical growth rates are not currently disclosed in the available financial data, preventing a direct comparison of earnings velocity against revenue expansion. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, which signifies that Soleno retains all of its earnings to reinvest into research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is standard for biotechnology companies aiming to advance their clinical pipelines and secure regulatory approval for their novel therapeutics before generating substantial cash flows for distribution. The overall growth and income profile of Soleno Therapeutics is characterized by a focus on capital appreciation through pipeline progression rather than income generation via dividends, aligning with the lifecycle of a pre-commercialization or early commercialization biopharmaceutical firm.